ロード中...
Experience with sunitinib in the treatment of metastatic renal cell carcinoma
Following approval of the oral, multitargeted tyrosine kinase inhibitor sunitinib malate for the treatment of patients with metastatic renal cell carcinoma (mRCC) in Europe and the USA in 2006, the agent has had a substantial impact on the treatment landscape in this setting. Sunitinib is now recomm...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3441135/ https://ncbi.nlm.nih.gov/pubmed/23024706 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287212454933 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|